264 related articles for article (PubMed ID: 17721703)
1. Key clinical issues in renal cancer: a challenge for proteomics.
Banks RE; Craven RA; Harnden P; Madaan S; Joyce A; Selby PJ
World J Urol; 2007 Dec; 25(6):537-56. PubMed ID: 17721703
[TBL] [Abstract][Full Text] [Related]
2. Renal cell carcinoma and proteomics.
Sandim V; Pereira DA; Ornellas AA; Alves G
Urol Int; 2010; 84(4):373-7. PubMed ID: 20224258
[TBL] [Abstract][Full Text] [Related]
3. The proteomic landscape of renal tumors.
Chinello C; L'imperio V; Stella M; Smith AJ; Bovo G; Grasso A; Grasso M; Raimondo F; Pitto M; Pagni F; Magni F
Expert Rev Proteomics; 2016 Dec; 13(12):1103-1120. PubMed ID: 27748142
[TBL] [Abstract][Full Text] [Related]
4. Pathway analysis of kidney cancer using proteomics and metabolic profiling.
Perroud B; Lee J; Valkova N; Dhirapong A; Lin PY; Fiehn O; Kültz D; Weiss RH
Mol Cancer; 2006 Nov; 5():64. PubMed ID: 17123452
[TBL] [Abstract][Full Text] [Related]
5. Molecular markers of prognosis in renal cell carcinoma: Insight into tumor biology helps define risk and provides targets for therapy.
Wood CG
J Surg Oncol; 2006 Sep; 94(4):264-5. PubMed ID: 16941531
[No Abstract] [Full Text] [Related]
6. Understanding and managing renal cell carcinoma: can proteomic studies contribute to clinical practice?
Craven RA; Banks RE
Contrib Nephrol; 2008; 160():88-106. PubMed ID: 18401164
[TBL] [Abstract][Full Text] [Related]
7. Comparative proteomic profiling identifies potential prognostic factors for human clear cell renal cell carcinoma.
Sun X; Zhang H; Luo L; Zhong K; Ma Y; Fan L; Fu D; Wan L
Oncol Rep; 2016 Dec; 36(6):3131-3138. PubMed ID: 27748938
[TBL] [Abstract][Full Text] [Related]
8. Proteomics of endometrial cancer diagnosis, treatment, and prognosis.
Mittal P; Klingler-Hoffmann M; Arentz G; Zhang C; Kaur G; Oehler MK; Hoffmann P
Proteomics Clin Appl; 2016 Mar; 10(3):217-29. PubMed ID: 26541900
[TBL] [Abstract][Full Text] [Related]
9. Immunodiagnosis of renal cell carcinoma.
Ebert T; Bander NH
Immunol Ser; 1990; 53():469-83. PubMed ID: 2100572
[TBL] [Abstract][Full Text] [Related]
10. Proteomic analysis reveals differentially secreted proteins in the urine from patients with clear cell renal cell carcinoma.
Sandim V; Pereira Dde A; Kalume DE; Oliveira-Carvalho AL; Ornellas AA; Soares MR; Alves G; Zingali RB
Urol Oncol; 2016 Jan; 34(1):5.e11-25. PubMed ID: 26420021
[TBL] [Abstract][Full Text] [Related]
11. iTRAQ-based quantitative proteomic analysis reveals potential early diagnostic markers of clear-cell Renal cell carcinoma.
Zhang L; Jiang H; Xu G; Chu N; Xu N; Wen H; Gu B; Liu J; Mao S; Na R; Jing Y; Ding Q; Zhang Y; Wang L
Biosci Trends; 2016 Jul; 10(3):210-9. PubMed ID: 27319973
[TBL] [Abstract][Full Text] [Related]
12. Current status and future directions of molecular markers in renal cell carcinoma.
Rini BI
Curr Opin Urol; 2006 Sep; 16(5):332-6. PubMed ID: 16905977
[TBL] [Abstract][Full Text] [Related]
13. PAX2 and PAX8 expression in primary and metastatic renal tumors: a comprehensive comparison.
Ozcan A; de la Roza G; Ro JY; Shen SS; Truong LD
Arch Pathol Lab Med; 2012 Dec; 136(12):1541-51. PubMed ID: 23194047
[TBL] [Abstract][Full Text] [Related]
14. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.
Stillebroer AB; Mulders PF; Boerman OC; Oyen WJ; Oosterwijk E
Eur Urol; 2010 Jul; 58(1):75-83. PubMed ID: 20359812
[TBL] [Abstract][Full Text] [Related]
15. Quantitative proteomics in resected renal cancer tissue for biomarker discovery and profiling.
Atrih A; Mudaliar MA; Zakikhani P; Lamont DJ; Huang JT; Bray SE; Barton G; Fleming S; Nabi G
Br J Cancer; 2014 Mar; 110(6):1622-33. PubMed ID: 24548857
[TBL] [Abstract][Full Text] [Related]
16. The utility of tetraspanin CD9 as a biomarker for metastatic clear cell renal cell carcinoma.
Garner JM; Herr MJ; Hodges KB; Jennings LK
Biochem Biophys Res Commun; 2016 Feb; 471(1):21-5. PubMed ID: 26855131
[TBL] [Abstract][Full Text] [Related]
17. Expression of the tumor-associated gene MN: a potential biomarker for human renal cell carcinoma.
McKiernan JM; Buttyan R; Bander NH; Stifelman MD; Katz AE; Chen MW; Olsson CA; Sawczuk IS
Cancer Res; 1997 Jun; 57(12):2362-5. PubMed ID: 9192809
[TBL] [Abstract][Full Text] [Related]
18. The expression of G250/mn/CA9 antigen by flow cytometry: its possible implication for detection of micrometastatic renal cancer cells.
Li G; Passebosc-Faure K; Lambert C; Gentil-Perret A; Blanc F; Oosterwijk E; Mosnier JF; Genin C; Tostain J
Clin Cancer Res; 2001 Jan; 7(1):89-92. PubMed ID: 11205923
[TBL] [Abstract][Full Text] [Related]
19. Role of carbonic anhydrase IX, α-methylacyl coenzyme a racemase, cytokeratin 7, and galectin-3 in the evaluation of renal neoplasms: a tissue microarray immunohistochemical study.
Bing Z; Lal P; Lu S; Ziober A; Tomaszewski JE
Ann Diagn Pathol; 2013 Feb; 17(1):58-62. PubMed ID: 22898056
[TBL] [Abstract][Full Text] [Related]
20. Proteomics of cancer of hormone-dependent tissues.
Tyson DR; Ornstein DK
Adv Exp Med Biol; 2008; 630():133-47. PubMed ID: 18637489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
